Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

at 6 months, p=0.015) and improved functional capacity (gain of 52.6 meters over 6 minutes' walk compared with controls at 12 months, p=0.06).

After 12 months, 40% of all treated patients had reverted to class I NYHA status compared with 14% of all controls, and this effect remained when patients were matched for the presence of class II status at baseline. The group who received the 25M MPC dose showed a significant 8.9 point improvement in ejection fraction over controls at 3 months (p=0.008), with a sustained but less pronounced effect over 12 months. In contrast, the group who received 150M MPC did not show improved ejection fraction, suggesting that the positive effects of this dose on clinical outcomes, remodeling, and functional capacity may be due to other mechanisms such as anti-fibrosis.

"These clinical findings are the first using any cell therapy in heart failure patients to show a concordant positive effect on clinical outcomes, cardiac remodelling, and functional capacity, the three key parameters in congestive heart failure.  Together, they indicate that a single 150 million dose of Revascor™ may significantly reduce both heart failure hospitalizations and death in these very sick patients who have such a poor prognosis despite maximal existing therapies," Dr Perin said.  

"Based on their defined product characterization, batch to batch consistency, immediate availability, and lack of clinically relevant immunogenicity, MPCs appear to be an ideal cell type to provide a new level of patient care in congestive heart failure.  We look forward to progressing the Revascor™ clinical program into Phase 3," Dr Perin added.

Revascor™ is being jointly developed by Mesoblast and its strategic alliance partner, Teva Pharmaceutical Industries Ltd.  

Teva's Corporate Vice President Global Branded Products, Kevin Buchi, said: "These independently-reviewed results serve to reinforce Teva's commi
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/21/2014)... (PRWEB) December 21, 2014 CannabisClassifieds.com celebrates marijuana’s ... The only one of its kind, the site has ... local marijuana for 14 years running. It uniquely combines ... to make cannabis readily available to the masses. Assuring ... grasping the golden ring of public approval. , ...
(Date:12/21/2014)... December 21, 2014 Concept Plus, LLC. ... firm headquartered in Fairfax, VA., today announced it has ... Fast 50 list, which ranks the fastest growing government contracting ... 2009 to 2013. , This is the first year that ... ranked # 20 with a 95.92% compound annual growth rate. ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new ... promotion of special occasion dresses for the coming new ... special occasion dresses for global women. Now, all the ... up to 80% off. Among the new items, the ... 16 Dress) is very popular. What’s more, Weddingshe.com also ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
Breaking Medicine News(10 mins):Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2
... campaign on health and hygiene in violence-hit Afghanistaqn from Saturday. ... aims to educate more than two million people in the ... begin in Kabul on June 24, targeting 850,000 people, before ... ,Each phase lasts 20 days, and will involve hundreds ...
... recent study has revealed that the place of birth determines the ... lower life expectancy than those born in south east England //. ... was found to be 69.3 it was found to be 77 ... the research and it has ranked the 10 best and worst ...
... District Health Boards and Primary Health Organisations, (PHOs), which faced ... both parties reaching an agreement on the extension of ... who are GP patients, aged between 45 - 64 years, ... GPs have long been at loggerheads over the conditions, ...
... Wilson, elected to undergo hysterectomy and mastectomy. due to a ... family harbors to develop breast cancer //. Oonagh’s decision came ... least two more years for the results of the genetic ... changes in service delivery and delays in getting licenses from ...
... acting chief has expressed doubts as to whether the $46 ... a mental health rehabilitation unit in the Riverina. ... for the Wagga clubhouse itself has been stalled by the ... Heath Minister they commented that the Lands Minister had approved ...
... According to a study conducted by Yale university researchers it was ... one's life resulted in an increased rate of heart attacks //. ... to 61 years. The results of the study were published in ... suffered from heart attacks and strokes in about 10 years time ...
Cached Medicine News:Health News:Life Expectancy Determined by Place of Birth 2Health News:Woman Elects For Mastectomy: Prolonged Wait For Genetic Results 2Health News:Woman Elects For Mastectomy: Prolonged Wait For Genetic Results 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: